For information only. Not investment advice, a recommendation, an offer or a solicitation, and without regard to any recipient’s objectives or circumstances. Figures come from third-party sources believed reliable but not guaranteed, and market data may be delayed. Past performance is not a reliable indicator of future results. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() Waters CorporationWAT US · Health Care · USD Current price$466.10as of Nov 19, 2026 Summary
Analyst consensusStrong Buy 3Buy 15Hold 5Strong Sell 123 analysts 3-year price (USD)Factor profileMulti-factor score 84 / 100 Market data
Business descriptionWaters Corporation (WAT) is a premier analytical instrument and specialty measurement company providing liquid chromatography (HPLC), mass spectrometry (MS), and thermal analysis (TA) technologies. Serving biopharmaceutical, clinical, academic, materials science, food safety, and environmental testing markets worldwide, Waters combines precision laboratory hardware with enterprise software and recurring chemistry consumables. Competitive moatWaters operates a highly defensible razor-and-blade business model where an entrenched global installed base of precision instruments drives ongoing, high-margin sales of proprietary consumables, chromatography columns, replacement parts, and informatics software contracts (representing over 50% of annual revenues). Its measurement tools are deeply validated into regulated pharmaceutical QA/QC (quality assurance/quality control) workflows, where switching instruments requires costly and time-consuming regulatory re-validation by FDA and global health agencies. Recent developments
Investment risks / red flags
Financials
Classification
|
Theme Exposure
Factor Profile (Spider Chart)
TBI ModelPrice Chart (TradingView)
Symbol: WATBusiness description
Waters Corporation (WAT) is a premier analytical instrument and specialty measurement company providing liquid chromatography (HPLC), mass spectrometry (MS), and thermal analysis (TA) technologies. Serving biopharmaceutical, clinical, academic, materials science, food safety, and environmental testing markets worldwide, Waters combines precision laboratory hardware with enterprise software and recurring chemistry consumables.
Competitive moat
Waters operates a highly defensible razor-and-blade business model where an entrenched global installed base of precision instruments drives ongoing, high-margin sales of proprietary consumables, chromatography columns, replacement parts, and informatics software contracts (representing over 50% of annual revenues). Its measurement tools are deeply validated into regulated pharmaceutical QA/QC (quality assurance/quality control) workflows, where switching instruments requires costly and time-consuming regulatory re-validation by FDA and global health agencies.
Recent developments
- Transformational Becton Dickinson BDS Merger ($18.8B): Closed the acquisition and combination of Becton Dickinson's Biosciences & Diagnostic Solutions (BDS) business on February 9, 2026. The transaction doubles Waters' addressable market by adding leading franchises in flow cytometry, single-cell multiomics, and clinical diagnostics, targeting $75 million in cost synergies and $50 million in revenue synergies in 2026.
- Combined Scale & Guidance Upward Revision: Combined FY 2026 sales projected at $6.415B–$6.476B (vs. $3.16B standalone in 2025). Full-year 2026 constant-currency organic revenue growth guidance was raised to 7%–9%, underpinned by strong biopharma demand and integration traction.
- China Market Inflection to Growth: Organic revenue in China inflected positively in 1H 2026, delivering double-digit growth among Chinese commercial biopharma customers and transitioning from a past drag to an active growth contributor.
- Secular Analytical Tailwinds: Accelerated instrument demand driven by the characterization and quality release of GLP-1 and incretin peptide therapies, rising PFAS forever-chemical testing mandates, and expanding commercial biomanufacturing in India.
Investment risks / red flags
- Post-merger integration complexity and financial leverage absorption following the $18.8 billion BDS acquisition.
- Cautious academic and government research funding spending trends in the United States and Europe.
- Ongoing healthcare reimbursement reforms in China, including DRG (Diagnosis-Related Group) hospital procurement pressures impacting diagnostic instrument adoption.
Market Data
Source: mkts.io · Nov 19, 2026, 14:00 UTC
Key Metrics
Analyst Consensus
Calendar Events
Financials
Forward Estimates
| Period | EPS Est | Rev Est |
|---|---|---|
| 0q | 4.65 | $1.81B |
| +1q | 3.21 | $1.61B |
| 0y | 14.67 | $6.49B |
| +1y | 16.53 | $7.17B |
Earnings
Rating Changes
| Date | Firm | Action | To |
|---|---|---|---|
| Nov 4, 2026 | Citigroup | main | Buy |
| Nov 4, 2026 | JP Morgan | main | Neutral |
| Nov 4, 2026 | TD Cowen | main | Buy |
| Nov 4, 2026 | Barclays | main | Overweight |
| Nov 4, 2026 | RBC Capital | main | Outperform |
| Nov 4, 2026 | Keybanc | main | Overweight |
